3
Participants
Start Date
September 3, 2014
Primary Completion Date
November 6, 2014
Study Completion Date
November 6, 2014
PF-03084014
Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
Gemcitabine
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Nab-paclitaxel
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
PF-03084014
Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
Gemcitabine
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Nab-paclitaxel
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Gemcitabine
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Nab-paclitaxel
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
University of Rochester Investigational Drug Pharmacy, Rochester
University of Rochester, Rochester
Anschutz Inpatient Pavilion, Aurora
University of Colorado Cancer Center, Aurora
University of Colorado Denver, CTO (CTRC), Aurora
Lead Sponsor
Academic GI Cancer Consortium (AGICC)
OTHER
Pfizer
INDUSTRY